BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Teijin Pharma's Febuxostat (FEBURIC) Launches in Taiwan - Novel Drug for Treatment of Hyperuricemia With Gout


5/10/2012 9:05:25 AM

Tokyo, Japan, May 10, 2012 --- Teijin Pharma Limited announced today the launch of febuxostat, a novel drug developed by Teijin Pharma for the treatment of hyperuricemia with gout, in Taiwan. Astellas Pharma Taiwan, Inc., the febuxostat licensee in Taiwan, is marketing the product under the brand name FEBURIC.

Teijin Pharma signed an exclusive licensing agreement with Astellas Pharma Taiwan in April 2009 for the development and marketing of febuxostat in Taiwan. In May 2011, Astellas Pharma Taiwan received approval from the Taiwan Department of Health to market the drug in the country for treatment of chronic hyperuricemia in patients with gout.

Discovered by Teijin Pharma, febuxostat is the world's first non-purine selective inhibitor of xanthine oxidase. It has a novel chemical structure completely different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia and gout. Taken once daily, febuxostat effectively reduces the level of uric acid in the blood of patients to the recommended level, and is well tolerated without need for dose adjustment in patients suffering from mild to moderate renal impairment.

Teijin Pharma has positioned febuxostat as a globally strategic product and expects to achieve annual global sales of 100 to 160 billion yen in the foreseeable future. Since March 2009, febuxostat has been marketed by licensees in the U.S., Canada, 15 European countries and Korea. In Japan, Teijin Pharma launched the drug in May 2011. Elsewhere, approvals have been obtained in Hong Kong, and collaborative arrangements have been formed with licensees in a total of 117 markets such as China, Turkey, Mexico and various counties of the Caribbean, Middle East and North African (MENA) regions, Central and South America, the Commonwealth of Independent States (CIS) and Oceania, covering all major markets worldwide.

About the Teijin Group

Teijin (TSE 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 17,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY 854.4 billion (USD 10.7 billion) and total assets of JPY 762.1 billion (USD 9.5billion) in the fiscal year ending March 31, 2012. Please visit www.teijin.co.jp/english.

Press Contact

Rie Mashiba

Public Relations Office

Teijin Limited

+81 3 3506 4055

pr@teijin.co.jp



Read at BioSpace.com

   
Gout

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES